

ASX Announcement | 28 June 2021
Visioneering Technologies (ASX:VTI)

Reverse Stock Split and Dispatch of Holding Statements

Atlanta, Georgia, Sunday, 27 June 2021 (Monday, 28 June 2021 Sydney time): US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, **Visioneering Technologies, Inc (ASX: VTI) (Visioneering or the Company)**, confirms that it has completed the reverse stock split of its securities on a 100 to 1 basis with any fractional entitlements being rounded up to the nearest whole number (**Reverse Stock Split**). The Reverse Stock Split was approved by securityholders at the Company's Annual Meeting of Stockholders held on 8 June 2021.

As a result of the Reverse Stock Split, the total number of CHES Despositary Interests (**CDIs**) on issue (representing the same number of shares of Class A common stock) has reduced from 2,264,679,811 to 22,647,141. The unlisted and listed options on issue have equally been consolidated on a 100 to 1 basis and the exercise price for such options amended in inverse to that ratio.

The Company is pleased to advise that it has today dispatched holding statements to securityholders advising them of their new holdings on a post Reverse Stock Split basis.

Ends.

This release was authorized by the CEO, Stephen Snowdy, PhD

For more information, please contact:

| Company |
|--|
| Stephen Snowdy, PhD CEO, Visioneering Technologies, Inc. E: ssnowdy@vtivision.com |

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is a health care company making innovative vision care products available to patients and eye care professionals. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from the healthcare industry to provide new solutions for adults and children in need of vision correction.

Headquartered in the United States, Visioneering designs, manufactures, sells and distributes contact lenses around the world. Its flagship product, NaturalVue® Multifocal contact lenses, are prescribed in the large addressable markets of nearsighted children and over-45 adults, and VTI is expanding its portfolio of technologies to address a range of other vision care needs. Since its IPO in 2017, the company has grown operations across the US and recently launched its products in Australia, New Zealand, Singapore, Hong Kong, Canada, and Europe.

Foreign ownership restrictions

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, plans and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.